Skip to main content
Top
Published in: Supportive Care in Cancer 12/2012

01-12-2012 | Original Article

French version of the Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog) version 3

Authors: F. Joly, M. Lange, O. Rigal, H. Correia, B. Giffard, J. L. Beaumont, S. Clisant, L. Wagner

Published in: Supportive Care in Cancer | Issue 12/2012

Login to get access

Abstract

Purpose

Impairment of cognitive function, a common complaint in patients receiving chemotherapy, is usually measured through neuropsychological tests. Patient self-evaluation of cognitive difficulties is an important complement to those tests. The Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog) is a self-report questionnaire with potential to be used in standard clinical practice as a tool for evaluating patient's cognitive function before, during, and after chemotherapy. The purpose of our study was to conduct linguistic validation of the French version of the FACT-Cog.

Methods

Both qualitative and quantitative methods were used in this study. After undergoing a rigorous translation methodology, the French FACT-Cog version was pretested in France with 35 cancer patients undergoing chemotherapy treatment. Interviews were conducted with all patients to ascertain their understanding of each item. The validation of the final version was conducted among 63 cancer patients, and sociodemographic information was collected as well as brief measure of cognitive function and depression score.

Results

Patient comments obtained through the cognitive debriefing interviews indicated that patients understand the French FACT-Cog items as they are intended and that the measure is culturally appropriate. Internal consistency reliability of the subscales, evaluated using Cronbach's coefficient alpha, was high for all four subscales: Perceived Cognitive Impairments = 0.93, Impact On QOL = 0.85, Comments From Others = 0.70, and Perceived Cognitive Abilities = 0.89. All item-total correlations for each subscale were greater than 0.20, and most were greater than 0.50.

Conclusions

Results from this study effectively demonstrate that the French FACT-Cog is a reliable instrument for the self-reporting of cognitive abilities in patients undergoing chemotherapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Schagen SB, Muller MJ, Boogerd W et al (2002) Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 13:1387–1397PubMedCrossRef Schagen SB, Muller MJ, Boogerd W et al (2002) Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 13:1387–1397PubMedCrossRef
2.
go back to reference Joly F, Rigal O, Noal S, Giffard B (2011) Cognitive dysfunction and cancer: which consequences in terms of disease management? Psychooncology Joly F, Rigal O, Noal S, Giffard B (2011) Cognitive dysfunction and cancer: which consequences in terms of disease management? Psychooncology
3.
go back to reference Lange M, Giffard B, Eustache F, Morel N, Noal S, Joly F (2011) Impact de la chimiothérapie adjuvante sur les fonctions cognitives dans le cancer du sein: revue de la littérature. Psycho-Oncologie 5:3–10CrossRef Lange M, Giffard B, Eustache F, Morel N, Noal S, Joly F (2011) Impact de la chimiothérapie adjuvante sur les fonctions cognitives dans le cancer du sein: revue de la littérature. Psycho-Oncologie 5:3–10CrossRef
4.
go back to reference Vardy J, Wong K, Yi QL et al (2006) Assessing cognitive function in cancer patients. Support Care Cancer 14:1111–1118PubMedCrossRef Vardy J, Wong K, Yi QL et al (2006) Assessing cognitive function in cancer patients. Support Care Cancer 14:1111–1118PubMedCrossRef
5.
go back to reference Pullens MJ, De Vries J, Roukema JA (2010) Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology 19:1127–1138PubMedCrossRef Pullens MJ, De Vries J, Roukema JA (2010) Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology 19:1127–1138PubMedCrossRef
6.
go back to reference Cimprich B, Visovatti M, Ronis DL (2011) The Attentional Function Index—a self-report cognitive measure. Psychooncology 20:194–202PubMedCrossRef Cimprich B, Visovatti M, Ronis DL (2011) The Attentional Function Index—a self-report cognitive measure. Psychooncology 20:194–202PubMedCrossRef
7.
go back to reference Suslow T, Arolt V, Junghanns K (1998) Differentielle validitat des Fragebogen erlebter Defizite der Aufmerksamkeit (FEDA): konkurrente validierungsergebnisse bei schizophrenen und depressiven patienten [in German]. Z Klin Psychol Psychiatr Psychother 46:152–165 Suslow T, Arolt V, Junghanns K (1998) Differentielle validitat des Fragebogen erlebter Defizite der Aufmerksamkeit (FEDA): konkurrente validierungsergebnisse bei schizophrenen und depressiven patienten [in German]. Z Klin Psychol Psychiatr Psychother 46:152–165
8.
go back to reference Wagner LI, Sabatino T, Cella D et al (2005) Cognitive function during cancer treatment: the FACT-Cog study. The J Robert H Lurie Compr Cancer Center Northwest Univ X:10–15 Wagner LI, Sabatino T, Cella D et al (2005) Cognitive function during cancer treatment: the FACT-Cog study. The J Robert H Lurie Compr Cancer Center Northwest Univ X:10–15
9.
go back to reference Wagner LI, Sweet J, Butt Z, Lai JS, Cella D (2009) Measuring patient self-reported cognitive function: development of the Functional Assessment of Cancer Therapy–Cognitive Function instrument. J Support Oncol 7:W32–W39 Wagner LI, Sweet J, Butt Z, Lai JS, Cella D (2009) Measuring patient self-reported cognitive function: development of the Functional Assessment of Cancer Therapy–Cognitive Function instrument. J Support Oncol 7:W32–W39
10.
go back to reference Eremenco SL, Cella D, Arnold BJ (2005) A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof 28:212–232PubMedCrossRef Eremenco SL, Cella D, Arnold BJ (2005) A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof 28:212–232PubMedCrossRef
11.
go back to reference Lent L, Hahn E, Eremenco S, Webster K, Cella D (1999) Using cross-cultural input to adapt the Functional Assessment of Chronic Illness Therapy (FACIT) scales. Acta Oncol 38:695–702PubMedCrossRef Lent L, Hahn E, Eremenco S, Webster K, Cella D (1999) Using cross-cultural input to adapt the Functional Assessment of Chronic Illness Therapy (FACIT) scales. Acta Oncol 38:695–702PubMedCrossRef
12.
go back to reference Bonomi AE, Cella DF, Hahn EA et al (1996) Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res 5:309–320PubMedCrossRef Bonomi AE, Cella DF, Hahn EA et al (1996) Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res 5:309–320PubMedCrossRef
13.
go back to reference Willis GB (ed) (2005) Cognitive interviewing: a tool for improving questionnaire design. Sage Publications, Thousand Oaks Willis GB (ed) (2005) Cognitive interviewing: a tool for improving questionnaire design. Sage Publications, Thousand Oaks
14.
go back to reference Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef
15.
16.
go back to reference Biglia N, Bounous VE, Malabaila A et al. (2011) Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care (Engl) Biglia N, Bounous VE, Malabaila A et al. (2011) Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care (Engl)
17.
go back to reference Spooner DM, Pachana NA (2006) Ecological validity in neuropsychological assessment: a case for greater consideration in research with neurologically intact populations. Arch Clin Neuropsychol 21:327–337PubMedCrossRef Spooner DM, Pachana NA (2006) Ecological validity in neuropsychological assessment: a case for greater consideration in research with neurologically intact populations. Arch Clin Neuropsychol 21:327–337PubMedCrossRef
18.
go back to reference Tannock IF, Ahles TA, Ganz PA, van Dam FS (2004) Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 22:2233–2239PubMedCrossRef Tannock IF, Ahles TA, Ganz PA, van Dam FS (2004) Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 22:2233–2239PubMedCrossRef
Metadata
Title
French version of the Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog) version 3
Authors
F. Joly
M. Lange
O. Rigal
H. Correia
B. Giffard
J. L. Beaumont
S. Clisant
L. Wagner
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 12/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1439-2

Other articles of this Issue 12/2012

Supportive Care in Cancer 12/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine